News

Michal Meron, MD, discusses her recent study indicating the potential role of the TYG index in predicting liver disease among patients without diabetes with confirmed MASLD.

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

FDA cited manufacturing and labeling issues in its CRL for cytisinicline, with no clinical efficacy or safety deficiencies reported.

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Butler explains why the urine albumin-to-creatinine ratio belongs in routine heart failure risk assessment and where the open questions remain.

Javed Butler, MD, MBA, discusses how aldosterone synthase inhibition could shift treatment across heart failure, CKD, and resistant hypertension.

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

Mona Shahriari, MD, spoke about the evolving understanding of atopic dermatitis as a systemic disease, the complexities of treatment selection, and more.

Multiple trials at RAD 2026 highlight the efficacy and safety of delgocitinib in chronic hand eczema.

RAD 2026 data indicate tralokinumab achieved significantly deeper hand eczema clearance and greater functional improvement than dupilumab in an indirect comparison.

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

Sarah Tomashefski, MSN, says persistent myths about who gets AATD and a failure to screen patients with any obstructive lung disease are driving a diagnostic gap APPs are uniquely positioned to close.

HCPLive convened an in-depth roundtable discussion on advancing biologic therapy for asthma and COPD in a complex real-world prescribing environment.

Nguyen urges clinicians to consider patient's disease presentation, comorbidities, treatment goals, and preferences when making therapeutic decisions.

At RAD 2026, Nguyen speaks on key highlights from his “Medical Crossfire” session, touching on the atopic dermatitis treatment landscape.

David Rosmarin, MD, discussed STAT6 inhibitors, ITK inhibitors, bispecifics, hand eczema, and endpoints at the RAD 2026 Conference.

At SDPA 2026, Shanna Miranti, PA-C, outlined how dermatology PAs can sharpen diagnostic speed and accuracy through structured visual practice and algorithm-based thinking.

Diana Varghese, MD, discusses her recent study noting a 9% prevalence of PA among patients with incident hypertension and providing targets for further screening strategies.

Song emphasized that clinicians should think beyond the skin when managing patients with atopic dermatitis.

ARCADIA LTE data show nemolizumab maintains EASI-75 in over 90% of responders through 2 years and phase 2 pediatric data shed further light at RAD 2026.

Pulmonologist David Hill, MD, anticipates cytisinicline's approval ahead of its June 20 PDUFA date.

At RAD2026, Lieberman notes advances in immunology and systemic therapies that are reshaping the link between dermatology and allergy/immunology.

A propensity-matched study shows dupilumab reduces gastrointestinal and endocrine IMID risk by 43-46% but raises psoriasis risk by 24%.